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Abstract
Introduction: Fistula formation in patients with Crohn’s disease is a common complication during
the course of the disease. Perianal and enteroenteric are the most common forms of fistulas, whereas
the involvement of the upper gastrointestinal tract with gastrocolic and duodenocolic fistulas
represents an extremely unusual condition. Moreover, hyperthyroidism in association with Crohn’s
disease has been rarely described.
Case presentation: We present here a rare case of a 25-year-old male with simultaneous onset of
hyperthyroidism and fistulizing Crohn’s disease. Crohn’s disease was complicated with intra-
abdominal fistulas involving the upper gastrointestinal tract (duodenocolic, gastrocolic) and an intra-
peritoneal abscess formation in the lesser sac. We describe the clinical presentation and therapeutic
management of the patient including both medical treatment and surgical intervention. Despite
intense medical treatment with total parenteral nutrition, antibiotics, aminosalicylates and
corticosteroids the clinical course of the disease was suboptimal. Finally, the patient underwent
laparotomy and right hemi-colectomy with ileo-transverse anastomosis performed, with simulta-
neous drainage of the abdominal abscess and primary closure of the upper gastrointestinal tract
openings (gastric, duodenal and jejunal) at one stage operation. Although the surgical approach
definitively cured the perforating complications of the disease (fistulas and abscess), the luminal
disease in the colon remnant was still active and steroid-refractory. The subsequent successful
treatment with infliximab, azathioprine and mesalazine resulted in the induction and maintenance of
the disease remission. Thyrotoxicosis was successfully treated with methimazole and the
hyperthyroidism has definitely subsided.
Page 1 of 6
(page number not for citation purposes)Conclusion: The management of intra-abdominal fistulas in Crohn’s disease is a complex issue,
requiring a multi-disciplinary approach and ‘tailoring’ of the treatment to the individual patient’s
needs. Probably, a sensible approach involves early surgical intervention with prior optimization of
the patient’s general condition when feasible. Common autoimmune mechanisms are probably
involved in thyroid dysfunction associated with Crohn’s disease. Moreover, diagnosis and treatment
of coexisting thyroid disorder in patients with Crohn’s disease has a favorable impact in disease
prognosis.
Introduction
Crohn’s disease (CD) is a chronic inflammatory disease of
unknown etiology characterized by a chronic, granuloma-
tous, segmental transmural inflammation that may affect
any part of the gastrointestinal (GI) tract.
The transmural nature of inflammation in CD predisposes
to the formation of fistulas. Fistulas are a common and
often serious complication of CD, occurring in 30% to
50% of CD patients during the course of their disease [1].
In general, fistulas are classified as external and internal
depending on their location and their connection with
adjacent structures. External fistulas connect a diseased part
of the bowel with the skin (enterocutaneous, parastomal
and perianal fistulas), whereas internal fistulas connect
either two parts of the bowel (enteroenteric, ileocolic,
gastrocolic, duodenocolic) or a diseased part of the bowel
and other adjacent organs (rectovaginal, enterovesical) [2].
Perianal fistulas are the most common type of fistulas in
CD patients, followed by internal enteroenteric fistulas,
while the involvement of the upper gastrointestinal tract
with gastrocolic and duodenocolic fistulas is very rare and
reported in few cases in the literature so far [1,3].
The coexistence of thyroid disease and inflammatory bowel
disease (IBD) is uncommon. Thyroid dysfunction has been
describedmorecommonlyinpatientswithulcerative colitis
(UC). On the contrary, its presence in patients with Crohn’s
disease is extremely rare [4,5]. We report a rare case of
simultaneous onset of hyperthyroidism and Crohn’s
disease complicated with intra-abdominal fistulas (duo-
denocolic, gastrocolic) and an intra-peritoneal abscess for-
mation in a 25-year-old male patient. We describe the
management of the patient, exposing the therapeutic
dilemmas that occurred, along with a review of the
literature of those rare complications and associations.
Case presentation
A 25-year-old, non-smoker, Caucasian male was admitted
to our department with a 10-day history of vomiting,
watery diarrheas, high fever (39
oC) and crampy
abdominal pain. His medical history was remarkable for
hyperthyroidism due to a thyrotoxic goiter diagnosed
4 months before. However, it was left untreated and the
patient mentioned a gradual body weight loss of 10 Kg
during the last four months. His family history was
unremarkable.
On admission the patient was febrile and looked severely
ill. His height and weight were 186 cm and 95 Kg
respectively (BMI 27.5 Kg/cm), and his vital signs included
a temperature of 39
oC, a blood pressure 130/80 mmHg,
and a heart rate of 130 beats per minute. Physical
examination revealed a mild to moderate tenderness at
the epigastrium and the right upper abdominal quadrant.
His thyroid gland was diffusely enlarged without tender-
ness. Laboratory data were remarkable for polymorpho-
nuclear leukocytosis (WBC 17 × 10
3/μl, neutrophils 77%),
thrombocytosis (PLT 540 × 10
3/μl), mild normocytic
anemia (Hb 11.8 g/dl, MCV 88 fl), hypoalbuminemia
(2.8 g/dl) and significantly elevated markers of inflamma-
tion (ESR 115 mm/1
st hr, CRP 126 mg/dl). Thyroid
function tests included low thyroid stimulating hormone
(TSH) (<0.03 μlU/ml; normal value 0.38-3.8 μlU/ml),
high serum free T4 (FT4) (2.86; normal value 0.75-
1.54 ng/dl) and normal serum free T3 (FT3) (3.7; normal
value 1-3.8 pg/ml). Anti-thyroid antibodies were also
elevated; the anti-thyroperoxidase antibody (anti-TPO) was
385.8 (normal value <50 IU/ml) and the anti-thyroglobulin
antibody (anti-TG) was 88.5 (normal value <50 IU/ml).
Ultrasonography of the thyroid gland revealed a multi-
nodular goitre, whereas
99mTc scan of the thyroid showed a
moderatethyroidglandenlargementwithincreased thyroid
gland total mass (32 gr; normal value <20 gr) and increased
homogenous parenchymal uptake of technetium pertech-
netate (4.78%; normal value 0.3-3%) (Figure 1). Treatment
for thyrotoxicosis was promptly started with propranolol
20 mg tid and methimazole 10 mg tid.
Soon after admission (2
nd day) the patient had bloody
diarrheas without signs of hypovolemic shock and
endoscopy of the upper and lower GI tract was performed.
Colonoscopy to the terminal ileum demonstrated mild
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friable and non-ulcerated mucosa without specific features
on histology, while the upper GI endoscopy showed a
normal esophagus, stomach and duodenum except for
two fistulous tract openings, one in the greater curve of the
stomach (Figure 2) and another in the second part of the
duodenum. The histologic examination of the biopsies
which were obtained from the fistulous openings showed
non-caseating granuloma formation (Figure 3), while the
random biopsies from the stomach and the duodenum
were normal without features of inflammatory bowel
disease.
Computed tomography (CT) scan of the abdomen and
pelvis showed an abscess formation without well-defined
margins (phlegmon) in the lesser sac (Figure 4A),
thickening of cecum, ascending and transverse colon
wall and localized thickening of the omentum and
mesentery (Figure 4B).
In the context of the findings above, treatment for severe
active fistulizing Crohn’s disease (CDAI score: 452)
complicated with an abdominal abscess was initiated
with the institution of total parenteral nutrition (TPN) and
the intravenous (IV) administration of high-dose predni-
solone (75 mg/day), ciprofloxacin (400 mg bid), metro-
nidazole (500 mg tid), and pantoprazole (40 mg bid),
along with oral mesalamine (3 g/day), and azathioprine
(2 mg/kg/day).
During the next 2 weeks, a gradual improvement of the
patient’s clinical and laboratory findings was noted and
barium upper GI series with a small-bowel follow-through
study were performed. The small bowel series showed a
colo-duodenal fistula between the ascending colon and
the second portion of the duodenum and multiple fistulas
between the jejunum and the lesser sac (Figure 5), whereas
the course of the gastric fistulous tract was not identified.
Figure 1. Thyroid Tc-99m scintigraphy. Diffusely increased
homogenous localization of technetium pertechnetate
(Tc-99m) in the thyroid gland. The gland looks enlarged, in
particular the left lobe.
Figure 2. Gastro-duodenoscopy. A fistulous tract (arrow)
opening on the greater curve at the antrum of the stomach
with a crater on the top of an inflammatory process.
Figure 3. Histology. Histologic examination of a biopsy taken
from the area of the fistulous tract opening in the stomach
showing a non-caseating granuloma formation (H&E, ¥400).
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condition remained stable with partial clinical improve-
ment under intense medical treatment, the clinical and
laboratory signs of a quiescent ‘brewing’ inflammation
were evident (ESR of 60 mm/1
st hour, CRP 60 mg/dl, low
grade temperature, clammy skin, heart rate of 90 beats
per minute), despite adequate control of the thyroid
function (TSH 1.55 μlU/ml, FT3 1.1 pg/ml, FT4 0.84 ng/
ml) and a CDAI score of 172. A second colonoscopy was
performed and revealed a stenotic area in the transverse
and ascending colon with erythematous, edematous, and
friable mucosa with ulcers and a fistulous tract opening at
the proximal transverse colon near to the hepatic flexure
(Figure 6).
Figure 4. Computed tomography of the abdomen. (A) CT of the abdomen shows an ill-defined intra-peritoneal phlegmon in the
lesser sac (continuous white arrow). (B) CT of the abdomen showing marked thickening of the wall of the ascending colon
(continuous white arrow), air-fluid collection in the right anterior pararenal space admixed with gastrographin (dotted white
arrow).
Figure 5. Small bowel barium follow-through study. Small-
bowel barium follow-through study revealing fistulous tracts
between the ascending colon and the 2
nd portion of the
duodenum (continuous white arrow) and between the
jejunum and the lesser sac (dotted white arrow).
Figure 6. Colonoscopy. Endoscopic appearance of a fistulous
tract opening in the proximal transverse colon near the
hepatic flexure (continuous white arrow).
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suboptimal clinical course of the disease, despite the
intense medical treatment, surgical intervention was
decided to be performed. Right hemi-colectomy with
ileo-transverse anastomosis, drainage of the abdominal
abscess and primary closure of the upper GI tract openings
(gastric, duodenal and jejunal) were performed at one
stage operation. The postoperative medical management
included oral steroids with gradual tapering, azathioprine,
mesalamine, and antibiotics with gradual introduction of
oral feeding. Still though, 3 weeks postoperatively, the
markers of inflammation were high (ESR 76 mm/1
st hr,
CRP 42 mg/l) and the patient was clammy and tachy-
cardiac with a heart rate of 90 beats per minute despite
good control of his thyroid function and a CDAI score of
105. Computed tomography (CT) scan of the abdomen
and pelvis was unremarkable for intraperitoneal abscess or
mass. At that point we decided to start anti-TNFa therapy
with infliximab and taper-off corticosteroids, since the
latter were proved insufficient in controling the disease.
Infliximab infusions (5 mg/kg) were well tolerated and
induced a sustained to date (36 months postoperatively)
endoscopic, clinical and biochemical response. Azathiopr-
ine and mesalamine are also continued as maintenance
treatment. The thyroid function maintains normal without
any treatment.
Discussion
The involvement of the upper GI tract in fistulizing
Crohn’s disease with gastrocolic and duodenocolic fistulas
is very rare (<1%). In most cases the fistulas arise from the
diseased small or large bowel. Pain located in the
epigastrium in association with nausea and vomiting are
the most common symptoms, while fecal vomiting is rare
[3,6,7]. Contrast imaging studies (barium enema or
meal and small bowel series) and endoscopy are the
most useful procedures for the diagnosis and evaluation of
the fistulas [7].
In our case the predominant symptoms (fever, diarrheas,
abdominal pain), were suggestive for colonic involve-
ment, whereas the presence of nausea and non-fecaloid
vomiting was not specific. Endoscopy of the upper and the
lower GI identified the fistulus openings in the stomach
and the duodenum, and the disease in the proximal colon,
respectively. Furthermore, histologic examination of the
biopsies confirmed the disease in the large bowel, while
the upper GI was uninvolved except for the fistulus
openings. On the other hand, the barium upper GI series
with small-bowel follow-through study identified the
course of the fistulus tracts.
The internal fistulas are thought to be indicative of a more
aggressive subtype of Crohn’s disease and often require
urgent and repeated surgical intervention. Although new
immunosuppressive agents (azathioprine, 6-mercaptopur-
ine, and infliximab) have been used for the treatment of
fistulas, the majority of data refer to perianal fistulas, while
controlled data for the efficacy of medical treatment in
healing of internal fistulas are lacking [8-10].
The presence of abscess formation is an important issue
and mustbe aggressively sought inpatients with fistulizing
Crohn’s disease. While a small abscess may be successfully
treated with antibiotics, larger abscesses require interven-
tion with percutaneous or surgical drainage [11,12]. The
control of the intestinal inflammation in the area of the
origin of an internal fistula and the control of the overall
Crohn’s disease activity is another important issue in
fistulizing Crohn’s disease. Corticosteroids, aminosalicy-
lates, and immunosuppressive agents (azathioprine,
6-mercaptopurine, and infliximab) are usually used to
treat luminal inflammatory disease. It is not uncommon,
however, for these modalities to fail in controlling the
inflammation and healing the concomitant abscesses or
internal fistulas [8].
Our patient presented intra-abdominal fistulas involving
the upper GI tract, accompanied by an abdominal abscess
formation in the lesser sac. His nutritional status and his
general clinical condition were quite poor on admission.
We followed an aggressive medical management with
hyper-alimentation (TPN), antibiotics, aminosalicylates
and immunosuppressive agents (corticosteroids and
azathioprine). Infliximab was not considered as the best
approach both because it could complicate the intra-
abdominal abscess with sepsis and because of the reported
low efficacy in healing internal fistulas [13]. We could not
perform percutaneous CT-guided drainage of the abscess
because it was not well defined (phlegmon) and located in
an area relatively difficult to access (lesser sac). The non-
invasive approach was finally unsuccessful, although the
patient’s general condition had improved.
In general, gastrocolic and duodenocolic fistulas represent
indications for surgery. Resection of the diseased segment
of the bowel containing the fistula (primary site of the
disease), resection of the fistula and primary repair of the
affected organ, has been proven so far to be the most
effective treatment method of intra-abdominal fistulas
and numerous operative approaches have been suggested
[3,6,10,14]. In our patient right hemi-colectomy with ileo-
transverse anastomosis, drainage of the abdominal abscess
and primary closure of the upper GI tract openings
(gastric, duodenal and jejunal) were performed at one
stage operation, without postoperative complications.
Whilethesurgicalapproachinourpatientdefinitivelycured
the perforating complications of the disease (fistulas and
abscess), the luminal disease in the colon remnant was still
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waseventuallysteroid-refractory,necessitatedtheuseofanti-
TNFa, that was no longer contraindicated after the draining
of the abscess, simultaneously with continuous use of
azathioprine and mesalazine [15].
Thyroid involvement in Crohn’s disease has also been
described in a few cases [4,5]. These reports show that
thyroid disease may occur before, concurrently or after the
onset of IBD [4,5]. Although there is still no clear
explanation for the coexistence of thyroid disease and
IBD, genetic or environmental factors may be implicated
in common pathogenetic mechanisms. Moreover, the
increased incidence of autoimmune diseases, including
autoimmune thyroid disease, in IBD may be immune-
mediated extraintestinal manifestations of IBD due to up-
regulated immune responses [4,5]. Our patient presented
with simultaneous occurrence of hyperthyroidism and
severe fistulizing Crohn’s disease. We believe that the
effective treatment of hyperthyroidism had a favorable
impact on the patient’s general health condition. This also
helped us to correctly associate the existence of clinical and
laboratory signs of the quiescent ‘brewing’ inflammation
with incomplete medical treatment of Crohn’s disease and
not with thyroid dysfunction.
Conclusion
The management of intra-abdominal fistulas in Crohn’s
disease is a complex issue, which requires a multi-
disciplinary approach and ‘tailoring’ of the treatment to
the individual patient’s needs. Probably a sensible
approach involves early surgical intervention with prior
optimization of the patient’s general condition when
feasible. Continuous immunosuppressive and anti-
inflammatory treatment post-operatively is necessary to
maintain the disease in remission and to prevent relapses.
Thyroid involvement in Crohn’s disease is also possible
and thyroid gland status should not be overlooked when
assessing an IBD patient with active inflammation.
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